Kuntal Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kuntal Pal has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Karsten Melcher
Department of Structural Biology, Van Andel Institute, Grand Rapids, MI 49503, USA
9 shared publications - H. Eric Xu
CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
8 shared publications - Kunchithapadam Swaminathan
Department of Biological Sciences National University of Singapore Singapore Singapore
4 shared publications Xiang Gao
Center for Cancer and Cell Biology, Program for Structural Biology, Van Andel Research Institute, Grand Rapids, USA
4 shared publicationsYanting Yin
The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
4 shared publications- Arkajit De
Van Andel Institute Graduate School, Grand Rapids, USA
3 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 6, 1846380
Computational design of immunogenic peptide–ligand conjugates for targeted therapy against Nipah virus infection
Introduction: Nipah virus (NiV) poses a major risk to global public health due to its high infectivity and associated mortality rates. Currently, no licensed vaccines or antiviral medications are available for NiV infection, leaving clinical management limited to supportive care. The viral receptor glycoprotein responsible for binding NiV to host cell receptors (ephrin-B2/B3) represents an ideal therapeutic target. This study proposes a novel peptide-ligand conjugate (PLC) immunotherapeutic approach that exploits pre-existing immune responses in NiV-endemic populations to selectively target and eliminate infected cells. Methods: We employed biomolecular modeling ( in silico ) to establish binding affinities and perform docking studies using a compound library obtained from the MolProphet database. A non-cleavable oxime linker was selected to enhance physical stability and ensure robust conjugation between ligand and peptide components. The peptide was engineered to contain immunogenic minimal epitope regions derived from measles, mumps, and rubella vaccines, selected based on their high immunization rates and long-lived memory responses in individuals residing in NiV-endemic areas. Results: The PLC design demonstrated selective binding capacity to a transmembrane protein present on NiV-infected cells. The oxime linker provided enhanced stability, and the peptide epitope design successfully incorporated regions associated with established long-term immunity. Discussion: This PLC system represents a promising framework for antiviral therapeutic development by harnessing pre-existing immune recognition to promote selective clearance of NiV-infected cells. The findings highlight critical structural components and functional roles of PLCs in therapeutic development, including drug target screening and rational design strategies for enhancing targeting specificity and molecular stability. Future work should focus on experimental validation of the computational predictions and in vitro / in vivo efficacy studies.
- 27 July 2026
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 6, 1846380
Open AccessComputational design of immunogenic peptide–ligand conjugates for targeted therapy against Nipah virus infection
Introduction: Nipah virus (NiV) poses a major risk to global public health due to its high infectivity and associated mortality rates. Currently, no licensed vaccines or antiviral medications are available for NiV infection, leaving clinical management limited to supportive care. The viral receptor glycoprotein responsible for binding NiV to host cell receptors (ephrin-B2/B3) represents an ideal therapeutic target. This study proposes a novel peptide-ligand conjugate (PLC) immunotherapeutic approach that exploits pre-existing immune responses in NiV-endemic populations to selectively target and eliminate infected cells. Methods: We employed biomolecular modeling ( in silico ) to establish binding affinities and perform docking studies using a compound library obtained from the MolProphet database. A non-cleavable oxime linker was selected to enhance physical stability and ensure robust conjugation between ligand and peptide components. The peptide was engineered to contain immunogenic minimal epitope regions derived from measles, mumps, and rubella vaccines, selected based on their high immunization rates and long-lived memory responses in individuals residing in NiV-endemic areas. Results: The PLC design demonstrated selective binding capacity to a transmembrane protein present on NiV-infected cells. The oxime linker provided enhanced stability, and the peptide epitope design successfully incorporated regions associated with established long-term immunity. Discussion: This PLC system represents a promising framework for antiviral therapeutic development by harnessing pre-existing immune recognition to promote selective clearance of NiV-infected cells. The findings highlight critical structural components and functional roles of PLCs in therapeutic development, including drug target screening and rational design strategies for enhancing targeting specificity and molecular stability. Future work should focus on experimental validation of the computational predictions and in vitro / in vivo efficacy studies.
- 29 January 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (5) , 1077-1102
A structural overview of G-protein-coupled receptors in neurological disorders
Neuropsychiatry and neurodegenerative disorders (NPDs and NDDs) are often associated with various physiological factors. It is increasingly apparent that signal transducers like G-protein-coupled receptors (GPCRs) are critical in disease progression and constitute an important class of drug targets. Several members of class A, class B, and class C GPCR families, along with their cognate binding partners, are involved in neurotransmission and neuromodulation. The vast information about the different molecular states of these GPCRs with their signaling complexes unravels the understanding of residual specificity in these protein-protein interactions and the dynamicity of transmembrane helices. The atypical mode of interaction of GPCRs with binding partners provides valuable insights for GPCR-conformation-based drug designing. In this review, we highlight the structural features of the serotonin, dopamine, and corticotropin receptors, namely 5-HTR1A, 5-HTR1B, 5-HTR2A, 5-HTR2B, 5-HTR2C, 5-HTR4, 5-HTR6, 5-HTR7, D1-5R, and CRF1-2R when forming transient complexes with G-proteins and arrestins. The distinct structural characteristics of these receptors explain the underlying molecular mechanism for signaling specificity and related physiological processes. This review also summarizes the importance of these structural insights in developing newer and effective pharmacologically biased drugs that can mediate specific signaling pathways to GPCRs.
- 29 January 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (5) , 1077-1102
A structural overview of G-protein-coupled receptors in neurological disorders
Neuropsychiatry and neurodegenerative disorders (NPDs and NDDs) are often associated with various physiological factors. It is increasingly apparent that signal transducers like G-protein-coupled receptors (GPCRs) are critical in disease progression and constitute an important class of drug targets. Several members of class A, class B, and class C GPCR families, along with their cognate binding partners, are involved in neurotransmission and neuromodulation. The vast information about the different molecular states of these GPCRs with their signaling complexes unravels the understanding of residual specificity in these protein-protein interactions and the dynamicity of transmembrane helices. The atypical mode of interaction of GPCRs with binding partners provides valuable insights for GPCR-conformation-based drug designing. In this review, we highlight the structural features of the serotonin, dopamine, and corticotropin receptors, namely 5-HTR1A, 5-HTR1B, 5-HTR2A, 5-HTR2B, 5-HTR2C, 5-HTR4, 5-HTR6, 5-HTR7, D1-5R, and CRF1-2R when forming transient complexes with G-proteins and arrestins. The distinct structural characteristics of these receptors explain the underlying molecular mechanism for signaling specificity and related physiological processes. This review also summarizes the importance of these structural insights in developing newer and effective pharmacologically biased drugs that can mediate specific signaling pathways to GPCRs.
- 1 January 2026
- Published by Springer Nature in Neuroinformatics
- Vol. 24 (1) , 14
A Comprehensive Analysis of Inflammation Regulatory Biomarkers among three Neuropsychiatric Disorders using Transcriptomic Approach
- 1 January 2026
- Published by Springer Nature in Neuroinformatics
- Vol. 24 (1) , 14
A Comprehensive Analysis of Inflammation Regulatory Biomarkers among three Neuropsychiatric Disorders using Transcriptomic Approach
- 4 October 2025
- Published by Elsevier
- p. 321-376
Natural pigments: From light perception to transformation of human health
- 4 October 2025
- Published by Elsevier
- p. 321-376
Natural pigments: From light perception to transformation of human health
- Open Access
- 23 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 33270-33287
Exploring the Microbial Peptides Derived from the Human Gut Microbiota to Regulate Class B GPCRS Using an In Silico Approach
Class B G-protein coupled receptors (GPCRs) are significant therapeutic recipients in cardiovascular, neurological, and metabolic diseases. The human gut microbiome is a complex microbial ecology recently identified as a possible source of bioactive peptides that control host physiological functions. Candidate peptides were found using advanced bioinformatics tools including sequence homology analysis, structure modeling, and molecular docking. These peptides were then evaluated for their binding affinity and potential functional regulation of the GPCR activity. Molecular dynamics simulations offered additional insights regarding the stability and interaction diversity of peptide-receptor complexes, highlighting receptor conformational state of G-protein interaction. The findings identify unique microbial peptides capable of influencing class B GPCR function, providing important insights into microbiome–host interactions and therapeutic potential. This study emphasizes the gut microbiome’s previously untapped potential as a source of GPCR modulators, opening up new avenues for microbiome-driven therapy approaches for metabolic and endocrine disorders.
- 23 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 33270-33287
Open AccessExploring the Microbial Peptides Derived from the Human Gut Microbiota to Regulate Class B GPCRS Using an In Silico Approach
Class B G-protein coupled receptors (GPCRs) are significant therapeutic recipients in cardiovascular, neurological, and metabolic diseases. The human gut microbiome is a complex microbial ecology recently identified as a possible source of bioactive peptides that control host physiological functions. Candidate peptides were found using advanced bioinformatics tools including sequence homology analysis, structure modeling, and molecular docking. These peptides were then evaluated for their binding affinity and potential functional regulation of the GPCR activity. Molecular dynamics simulations offered additional insights regarding the stability and interaction diversity of peptide-receptor complexes, highlighting receptor conformational state of G-protein interaction. The findings identify unique microbial peptides capable of influencing class B GPCR function, providing important insights into microbiome–host interactions and therapeutic potential. This study emphasizes the gut microbiome’s previously untapped potential as a source of GPCR modulators, opening up new avenues for microbiome-driven therapy approaches for metabolic and endocrine disorders.
- 24 April 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (2) , 70
In silico drug repurposing of potential antiviral inhibitors targeting methyltransferase (2′-O-MTase) domain of Marburg virus
Marburg Virus (MARV) presents a significant threat to human health, highlighting the urgent need for effective therapeutics. The MARV genome encodes a multifunctional ‘large’ L protein that plays a crucial role in polymerase, capping, and methyltransferase activities. Within this protein, the 2′-O-methyltransferase (2′-O-MTase) domain is essential for viral replication and immune evasion, making it a promising therapeutic target. However, the lack of structural data on this domain limits drug discovery efforts. To address this challenge, we utilized AlphaFold2 to predict a 3D structure of the MARV 2′-O-MTase domain. Molecular docking with its natural ligand, S-adenosyl methionine (SAM), allowed us to identify key active-site residues involved in ligand binding. We then screened 62 known inhibitors against this domain and identified four promising candidates: Lifirafenib (− 9.5 kcal/mol), Dolutegravir (− 8.5 kcal/mol), BRD3969 (− 8.3 kcal/mol), and JFD00244 (− 8.2 kcal/mol). Further, we assessed the pharmacokinetic and pharmacodynamic properties of these compounds to evaluate their drug-likeness. Molecular dynamics simulations, along with MM/GBSA free energy calculations, confirmed stable interactions between the selected inhibitors and the target domain. While these findings highlight promising candidates for MARV, experimental validation through in vitro and in vivo assays is essential to assess their safety and efficacy. Graphical abstract The alternative text for this image may have been generated using AI.
- 24 April 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (2) , 70
In silico drug repurposing of potential antiviral inhibitors targeting methyltransferase (2′-O-MTase) domain of Marburg virus
Marburg Virus (MARV) presents a significant threat to human health, highlighting the urgent need for effective therapeutics. The MARV genome encodes a multifunctional ‘large’ L protein that plays a crucial role in polymerase, capping, and methyltransferase activities. Within this protein, the 2′-O-methyltransferase (2′-O-MTase) domain is essential for viral replication and immune evasion, making it a promising therapeutic target. However, the lack of structural data on this domain limits drug discovery efforts. To address this challenge, we utilized AlphaFold2 to predict a 3D structure of the MARV 2′-O-MTase domain. Molecular docking with its natural ligand, S-adenosyl methionine (SAM), allowed us to identify key active-site residues involved in ligand binding. We then screened 62 known inhibitors against this domain and identified four promising candidates: Lifirafenib (− 9.5 kcal/mol), Dolutegravir (− 8.5 kcal/mol), BRD3969 (− 8.3 kcal/mol), and JFD00244 (− 8.2 kcal/mol). Further, we assessed the pharmacokinetic and pharmacodynamic properties of these compounds to evaluate their drug-likeness. Molecular dynamics simulations, along with MM/GBSA free energy calculations, confirmed stable interactions between the selected inhibitors and the target domain. While these findings highlight promising candidates for MARV, experimental validation through in vitro and in vivo assays is essential to assess their safety and efficacy. Graphical abstract The alternative text for this image may have been generated using AI.
- Open Access
- 15 March 2024
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 12 (1) , 138-144
Residue-specific orientation of arrestin in 5-HTR1B (Serotonin Receptor)- βArrestin-1 interaction
Physiologically G protein-coupled receptors (GPCRs) are an important class of cell surface proteins capable of sensing the exogenous signals across the cell membrane through G-protein-dependent and independent pathways. Activated GPCRs initiate diverse G-protein-independent signalling through interaction with arrestin. Arrestins comprise a family of four proteins that act as signal regulators of GPCRs. Arrestin specificity and assembly orientation with a particular GPCR depend on the finger loop's residues. Recent cryo-EM structural elucidation of neurotensin receptor-1(NTSR1)-β-arrestin1complex reveals its striking difference from Rhodopsin-visual-Arrestin by a 90˚ rotation of β-Arrestin1 concerning the receptor. Alignment of neurotensin receptor 1(NTSR1)-β-Arrestin1 assembly with 5-HTR1B (Serotonin receptor) structure shows an ionic interaction mediated complex formation between receptor binding cleft and finger loop of arrestin. Mutational analysis of finger loop residues R65, D67, and D69 of β-Arrestin1 by tango assay confirms its possible interaction with an electropositive pocket of K79 and R161 in 5-HTR1B.
- 15 March 2024
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 12 (1) , 138-144
Open AccessResidue-specific orientation of arrestin in 5-HTR1B (Serotonin Receptor)- βArrestin-1 interaction
Physiologically G protein-coupled receptors (GPCRs) are an important class of cell surface proteins capable of sensing the exogenous signals across the cell membrane through G-protein-dependent and independent pathways. Activated GPCRs initiate diverse G-protein-independent signalling through interaction with arrestin. Arrestins comprise a family of four proteins that act as signal regulators of GPCRs. Arrestin specificity and assembly orientation with a particular GPCR depend on the finger loop's residues. Recent cryo-EM structural elucidation of neurotensin receptor-1(NTSR1)-β-arrestin1complex reveals its striking difference from Rhodopsin-visual-Arrestin by a 90˚ rotation of β-Arrestin1 concerning the receptor. Alignment of neurotensin receptor 1(NTSR1)-β-Arrestin1 assembly with 5-HTR1B (Serotonin receptor) structure shows an ionic interaction mediated complex formation between receptor binding cleft and finger loop of arrestin. Mutational analysis of finger loop residues R65, D67, and D69 of β-Arrestin1 by tango assay confirms its possible interaction with an electropositive pocket of K79 and R161 in 5-HTR1B.
- Open Access
- 15 March 2024
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 12 (1) , 153-162
Molecular regulation of Mycobacterium tuberculosis Sigma factor H with Anti-sigma factor RshA under stress condition
Mycobacterium tuberculosis is the causative agent of tuberculosis, the leading fatal infectious disease that claims millions of lives every year. M. tuberculosis regulates its stress condition response using its regulatory protein, Sigma Factor H, which binds with its cognate anti-sigma factor RshA in normal conditions, forming a complex inhibiting transcription. During oxidative stress, SigH is released from the complex and binds to RNA Polymerase (RNAP) to initiate transcription. Thus, it is important to understand the molecular conformational state of SigH in complex with different protein partners under different cellular or environmental contexts. This work intends to analyze the SigH-RshA complex, which revealed the variation in SigH shown during complex formation with RNAP and RshA, respectively. Previously, Hydrogen Deuterium Exchange-Mass Spectrometry (HDX-MS) analysis of SigH-RshA interaction provided a detailed insight into the critical residues participating in the interaction. The HDX-MS data were used to dock RshA on the open conformation of SigH from the SigH-RNAP complex structure (PDB: 5ZX2), and closed conformation was obtained from protein modelling. The docking revealed that closed conformation of SigH complexing with RshA in terms of HDX-MS data revealed a major structural shift in SigH while interacting with two different binding partners, RshA and RNAP, under variable environmental conditions. This structural shift of SigH with RshA and RNAP has significance in understanding the stress response of M. tuberculosis, and SigH could prove to be a potential drug target.
- 15 March 2024
- Published by Journal of Experimental Biology and Agricultural Sciences in Journal of Experimental Biology and Agricultural Sciences
- Vol. 12 (1) , 153-162
Open AccessMolecular regulation of Mycobacterium tuberculosis Sigma factor H with Anti-sigma factor RshA under stress condition
Mycobacterium tuberculosis is the causative agent of tuberculosis, the leading fatal infectious disease that claims millions of lives every year. M. tuberculosis regulates its stress condition response using its regulatory protein, Sigma Factor H, which binds with its cognate anti-sigma factor RshA in normal conditions, forming a complex inhibiting transcription. During oxidative stress, SigH is released from the complex and binds to RNA Polymerase (RNAP) to initiate transcription. Thus, it is important to understand the molecular conformational state of SigH in complex with different protein partners under different cellular or environmental contexts. This work intends to analyze the SigH-RshA complex, which revealed the variation in SigH shown during complex formation with RNAP and RshA, respectively. Previously, Hydrogen Deuterium Exchange-Mass Spectrometry (HDX-MS) analysis of SigH-RshA interaction provided a detailed insight into the critical residues participating in the interaction. The HDX-MS data were used to dock RshA on the open conformation of SigH from the SigH-RNAP complex structure (PDB: 5ZX2), and closed conformation was obtained from protein modelling. The docking revealed that closed conformation of SigH complexing with RshA in terms of HDX-MS data revealed a major structural shift in SigH while interacting with two different binding partners, RshA and RNAP, under variable environmental conditions. This structural shift of SigH with RshA and RNAP has significance in understanding the stress response of M. tuberculosis, and SigH could prove to be a potential drug target.
- Open Access
- 3 December 2023
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 14 (6) , 100825
In silico screening of herbal phytochemicals to develop a Rasayana for immunity against Nipah virus
- 3 December 2023
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 14 (6) , 100825
Open AccessIn silico screening of herbal phytochemicals to develop a Rasayana for immunity against Nipah virus